HTB South

Side effects

Studies on dolutegravir and sleep, cardiovascular and CNS side effects, and risk of IRIS

High rates of undocumented efavirenz-related side effects in Uganda

Further reports of CNS-related side effects with dolutegravir

Efavirenz associated with suicide risk in analysis from START study

Increased cardiovascular risks in HIV positive children in Uganda and Zambia partially reversed by ART

Risk of CVD or type-2 diabetes according to change in BMI after starting ART

Rosuvastatin may be partially effective in moderating residual immune activation on ART

Kidney signal trouble worsens over 5 years in Japanese on tenofovir

Bone mineral density linked to inflammatory markers in HIV positive people who are ART naïve

Abacavir link to cardiovascular events in high-risk patients maintained in D:A:D study

Two percent rate of efavirenz discontinuation in an ART programme in Malawi

Longitudinal changes in weight, lean body mass and bone mineral density in first-line combinations: ACTG 5205 substudy

ARVs and bone health: the role of NRTIs in second-line therapy

Ending global use of d4T: UNITAID to tip market to safer alternatives

Statin use in HIV positive people

No impact of ART on progression or regression of anal squamous intraepithelial lesions

Osteonecrosis in HIV positive patients is associated with increased levels of CRP and D-dimer

Cognitive disorders are common in French cohort but are not HIV-related

Smoking is largest contributor to reduced life expectancy in Danish HIV cohort

Low bone mineral density in MSM irrespective of HIV status

Increased incidence of ischemic stroke amongst HIV positive cohort

First report: atazanavir-related gallstones (cholelithiasis)

High prevalence of peripheral neuropathy in children taking d4T in rural South Africa

Skeletal muscle toxicity and raltegravir

Proteinuria as a potential early marker of tenofovir-related renal toxicity

Earlier and greater comorbidities reported in HIV positive cohort

Recent studies on HIV, ART and osteoporotic fracture risk

No association between atazanavir and MI or stroke in D:A:D study

Associations between tenofovir use and renal complications in VA cohort

Risk factors associated with End Stage Renal Disease (ESRD) in HIV positive patients in the US Veterans Association (VA) cohort

20% people switch Atripla due to efavirenz side effects: late switches are common

Hearing loss not associated with HIV in MACS and WIHS cohorts

More metabolic abnormalities in children receiving a PI compared to NNRTI in NEVEREST study

Lopinavir/ritonavir oral solution toxicity in neonates

Tenofovir associated with fewer side-effect related switches compared to AZT or d4T in first-line treatment

Nevirapine exposure was not associated with hypersensitivity in patients from Malawi

HIV-positive people in the HOPS cohort have 4-fold risk of fracture compared to general population in the US

Vitamin D deficiencies in HIV management

Central fat accumulation remains a significant problem in patients starting HAART after 2005 with higher incidence in women compared to men

HIV disease and renal function

11th International Workshop on Adverse Drug Reactions and Comorbidities in HIV (IWADR) 26-28 October 2009, Philadelphia

Association between inflammation and sleep apnea in the MACS cohort

Sports supplements impact on serum creatinine and eGFR markers of renal function

Gender and race differences in lipodystrophy symptoms

High incidence and risk factors for diabetes in French cohort

Intermuscular tissue is decreased in HIV infection

Assessing the cardiovascular impact of HIV, abacavir, and new signals for lopinavir/r

HDL particle concentration predicts cardiovascular disease in SMART

CD4 count >250 not predictive of rash-associated hepatoxicity among women initiating nevirapine-based ART in Zambia, Thailand, and Kenya

Genetic markers linked to early discontinuation of three antiretrovirals

Renal tubule damage with tenofovir despite normal glomerular function

Non alcoholic fatty liver disease (NAFLD) is common among HIV-positive patients

Bone loss in SMART study

Abacavir and heart disease: SMART study supports an abacavir-associated increased risk of cardiovascular disease